Role of DAF in protecting against T-cell autoreactivity that leads to experimental autoimmune uveitis

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 8, 2009, Pages 3778-3782

  An, Fengqi ^a   Li, Qing ^a,b   Tu, Zhidan ^a,b   Bu, Hong ^b   Chan, Chi Chao ^c   Caspi, Rachel R ^c   Lin, Feng ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b SICHUAN UNIVERSITY   (China)

^c NATIONAL EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 3; INTERPHOTORECEPTOR RETINOID BINDING PROTEIN; RECOMBINANT DECAY ACCELERATING FACTOR; RECOMBINANT PROTEIN; RETINA ANTIGEN; UNCLASSIFIED DRUG; DECAY ACCELERATING FACTOR; EYE PROTEIN; INTERLEUKIN 17; INTERSTITIAL RETINOL-BINDING PROTEIN; RETINOL BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; C57BL 10 MOUSE; CELL TRANSPORT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MECHANISM; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; INCIDENCE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PHOTORECEPTOR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETINA; RETINA INJURY; T LYMPHOCYTE; TH1 CELL; TH17 CELL; UPREGULATION; UVEITIS; VASCULITIS; WILD TYPE; ANIMAL; C57BL MOUSE; DISEASE MODEL; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD55; AUTOIMMUNE DISEASES; AUTOIMMUNITY; DISEASE MODELS, ANIMAL; EYE PROTEINS; INTERFERON-GAMMA; INTERLEUKIN-17; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECOMBINANT PROTEINS; RETINOL-BINDING PROTEINS; TH1 CELLS; UVEITIS, POSTERIOR;

EID: 68349083457     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-3264     Document Type: Article

References (38)

1. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology. 2004;111:491-500; discussion, 500.
2. Agarwal RK, Caspi RR. Rodent models of experimental autoimmune uveitis. Methods Mol Med. 2004;102:395-419.
3. Pepperberg DR, Okajima TL, Wiggert B, Ripps H, Crouch RK, Chader GJ. Interphotoreceptor retinoid-binding protein (IRBP): molecular biology and physiological role in the visual cycle of rhodopsin. Mol Neurobiol. 1993;7:61- 85.
4. Singh VK, Biswas S, Anand R, Agarwal SS. Experimental autoimmune uveitis as animal model for human posterior uveitis. Indian J Med Res. 1998;107:53-67.
5. Singh VK, Rai G. Cytokines in posterior uveitis: an update. Immunol Res. 2001;23:59-74.
6. de Kozak Y, Naud MC, Bellot J, Faure JP, Hicks D. Differential tumor necrosis factor expression by resident retinal cells from experimental uveitis-susceptible and -resistant rat strains. J Neuroimmunol. 1994;55:1-9.
7. Caspi RR. Th1 and Th2 responses in pathogenesis and regulation of experimental autoimmune uveoretinitis. Int Rev Immunol. 2002;21:197-208.
8. Caspi RR. Immune mechanisms in uveitis. Springer Semin Immunopathol. 1999;21:113-124.
9. Amadi-Obi A, Yu CR, Liu X, et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med. 2007;13:711-718.
10. Peng Y, Han G, Shao H, Wang Y, Kaplan HJ, Sun D. Characterization of IL-17+ interphotoreceptor retinoid-binding protein-specific T cells in experimental autoimmune uveitis. Invest Ophthalmol Vis Sci. 2007;48:4153-4161.
11. Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K. Cytokine profile in Behcet's disease patients: relationship with disease activity. Scand J Rheumatol. 2002;31:205-210.
12. Luger D, Silver PB, Tang J, et al. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med. 2008;205:799-810.
13. Heeger PS, Lalli PN, Lin F, et al. Decay-accelerating factor modulates induction of T cell immunity. J Exp Med. 2005;201:1523-1530.
14. Liu J, Miwa T, Hilliard B, et al. The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J Exp Med. 2005;201:567-577.
15. Medof ME, Kinoshita T, Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decayaccelerating factor (DAF) into their membranes. J Exp Med. 1984; 160:1558-1578.
16. Strainic MG, Liu J, Huang D, et al. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity. 2008;28:425-435.
17. Lalli PN, Strainic MG, Yang M, Lin F, Medof ME, Heeger PS. Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis. Blood. 2008;112:1759-1766.
18. Liu J, Lin F, Strainic MG, et al. IFN-gamma and IL-17 production in experimental autoimmune encephalomyelitis depends on local APC-T cell complement production. J Immunol. 2008;180:5882-5889.
19. Lin F, Fukuoka Y, Spicer A, et al. Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes: exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies. Immunology. 2001;104:215-225.
20. Chan CC, Caspi RR, Ni M, et al. Pathology of experimental autoimmune uveoretinitis in mice. J Autoimmun. 1990;3:247-255.
21. Lin F, Immormino RM, Shoham M, Medof ME. Bulk production and functional analyses of mouse CD55's native and deglycosylated active domains. Arch Biochem Biophys. 2001;393:67-72.
22. Berruyer C, Pouyet L, Millet V, et al. Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor gamma activity. J Exp Med. 2006;203:2817-2827.
23. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol. 2008;8:533-544.
24. Campbell IK, Rich MJ, Bischof RJ, Dunn AR, Grail D, Hamilton JA. Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice. J Immunol. 1998; 161:3639-3644.
25. Lawlor KE, Wong PK, Campbell IK, van Rooijen N, Wicks IP. Acute CD4 T lymphocyte-dependent interleukin-1-driven arthritis selectively requires interleukin-2 and interleukin-4, joint macrophages, granulocyte-macrophage colony-stimulating factor, interleukin- 6, and leukemia inhibitory factor. Arthritis Rheum. 2005; 52:3749-3754.
26. McQualter JL, Darwiche R, Ewing C, et al. Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. J Exp Med. 2001;194:873-882.
27. Ponomarev ED, Shriver LP, Maresz K, Pedras-Vasconcelos J, Verthelyi D, Dittel BN. GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis. J Immunol. 2007; 178:39-48.
28. Lang RA,. Metcalf D, Cuthbertson RA, et al. Transgenic mice expressing a hemopoietic growth factor gene (GM-CSF) develop accumulations of macrophages, blindness, and a fatal syndrome of tissue damage. Cell.1987;51:675-686.
29. Read RW, Szalai AJ, Vogt SD, McGwin G, Barnum SR. Genetic deficiency of C3 as well as CNS-targeted expression of the complement inhibitor sCrry ameliorates experimental autoimmune uveoretinitis. Exp Eye Res. 2006;82:389-394.
30. Molina H, Wong W, Kinoshita Brenner TC, Fole S, Holers VM. Distinct receptor and regulatory properties of recombinant mouse complement receptor 1 (CR1) and Crry, the two genetic homologues of human CR1. J Exp Med. 1992;175:121-129.
31. Lin F, Emancipator SN, Salant DJ, Medof ME. Decay-accelerating factor confers protection against complement-mediated podocyte injury in acute nephrotoxic nephritis. Lab Invest. 2002;82:563-569.
32. Lalli PN, Strainic MG, Lin F, Medof ME, Heeger PS. Decay accelerating factor can control T cell differentiation into IFN-gammaproducing effector cells via regulating local C5a-induced IL-12 production. J Immunol. 2007;179:5793-5802.
33. Sohn JH, Kaplan HJ, Suk HJ, Bora PS, Bora NS. Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins. Invest Ophthalmol Vis Sci. 2000; 41:3492-3502.
34. Jha P, Sohn JH Xu Q, et al. Suppression of complement regulatory proteins (CRPs) exacerbates experimental autoimmune anterior uveitis (EAAU). J Immunol. 2006;176:7221-7231.
35. Bora NS, Woon MD, Tandhasetti TM, Cirrito TP, Kaplan HJ. Induction of experimental autoimmune anterior uveitis by a self-antigen: melanin complex without adjuvant. Invest Ophthalmol Vis Sci. 1997;38:2171-2175.
36. Liao T, Ke Y, Shao WH, et al. Blockade of the interaction of leukotriene b4 with its receptor prevents development of autoimmune uveitis. Invest Ophthalmol Vis Sci. 2006;47:1543-1549.
37. Mason JC, Ahmed Z, Mankoff R, Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury. Circ Res. 2002;91:696-703.
38. Kohno H, Sakai T, Saito S, Okano K, Kitahara K. Treatment of experimental autoimmune uveoretinitis with atorvastatin and lovastatin. Exp Eye Res. 2007;84:569-576.